Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: ISIBLOOM — Supplemental Application (Xiromed, LLC.)

View source ↗

Summary

The FDA approved a supplemental application for ISIBLOOM, a desogestrel and ethinyl estradiol oral contraceptive from Xiromed, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ISIBLOOM (DESOGESTREL AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for ISIBLOOM (DESOGESTREL AND ETHINYL ESTRADIOL)